abrdn Life Sciences Investors 

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

abrdn Healthcare Investors operates as a closed-end investment fund, which engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

Adams Diversified Equity Fund

Barings Global Short Duration High Yield Fund

Calamos Strategic Total Return Fund

Chevron

Enterprise Products Partners

General American Investors

India Fund Inc

JPMorgan Chase & Co

New Linde PLC

Eli Lilly

Marathon Oil

Microsoft

Neuberger Berman MLP Income Fund, Inc.

NVIDIA

Adams Natural Resources Fund Inc

LMP Capital and Income Fund

Columbia Seligman Premium Technology Growth Func Inc

XAI Octagon Floating Rate & Alternative Income Term Trust

Energy Select Sector SPDR Fund

Exxon Mobil

For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.

5 Best CEFs This Month For 8.5% Yield (November 2024)

BlackRock Science & Technology

Eaton Vance Tax-Managed Diversified Equity Income Fund

GAMCO Global Gold. Natural Resources & Income Trust

Liberty All Star Equity Fund

For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.

5 Best CEFs This Month For 9.5% Yield (October 2024)

ArrowMark Financial

ConocoPhillips

EOG Resources

Eaton Vance Enhanced Equity Income Fund

5 Best CEFs This Month For 9% Plus Yield (September 2024)

BlackRock Capital Allocation Trust

Blackrock ESG Capital Allocation Trust

Gabelli Dividend & Income Trust

Closed-end funds have unique features that make them very attractive investment vehicles for the right asset classes and investors who understand them. Especially for complex and/or less liquid asset classes, like corporate senior loans, high-yield bonds, collateralized loan obligations, and the more recently discovered (by retail investors) "private credit" Activist and institutional investors are worth watching, so we can piggyback onto their efforts in the closed-end fund world.

Finding Opportunities In The Closed-End Fund World

abrdn Healthcare Investors 

abrdn World Healthcare Fund 

PHILADELPHIA, PA / ACCESSWIRE / March 21, 2024 / abrdn Healthcare Investors (NYSE:HQH), abrdn Life Sciences Investors (NYSE:HQL), abrdn Healthcare Opportunities Fund (NYSE:THQ), and abrdn World Healthcare Fund (NYSE:THW) (collectively, the "Funds") each, a closed-end management investment company, announced today the appointment of Dr. Jason Akus as co-lead portfolio manager to the Funds alongside Dr. Daniel Omstead. Dr. Akus has served on the investment team with Dr. Omstead for over 20 years.

abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW) Announce Investment Team Update

PHILADELPHIA, PA / ACCESSWIRE / February 9, 2024 / abrdn Life Sciences Investors (HQL), abrdn Healthcare Investors (HQH), and abrdn Healthcare Opportunities Fund (THQ) (collectively, the "Funds") each, a closed-end management investment company, announced today its Board of Trustees (each a "Board" and collectively, the "Boards") have approved an increase in each Fund's respective distribution rate and announce payment details for the Funds in the chart directly below. Ticker Exchange Fund Distribution Policy Previous Distribution Policy New Declared Distribution Amount HQH NYSE abrdn Healthcare Investors Annualized rate of 8% of rolling NAV Annualized rate of 10% of rolling NAV $ 0.4800 HQL NYSE abrdn Life Sciences Investors Annualized rate of 8% of rolling NAV Annualized rate of 10% of rolling NAV $ 0.3900 THQ NYSE abrdn Healthcare Opportunities Fund $0.1125 per share per month $0.18 per share per month $ 0.1800 HQL and HQH each distribute quarterly, and THQ distributes monthly all or a portion of its net investment income, including current gains, to common shareholders.

abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH) Announce a 25% Increase in Distribution Rates and abrdn Healthcare Opportunities Fund (THQ) Announces a 60% Increase in Distribution Rate

BlackRock Taxable Municipal Bond Trust

Blackrock Core Bond Trust

John Hancock Financial Opportunities Fund

Brandywine Global Income Opportunities Fund Inc

Virtus Stone Harbor Emerging Markets Income Fund 

CBRE Global Real Estate Income Fund

Nuveen Build America Bond Fund

For the second consecutive month, both equity (+3.42% on a NAV basis) and fixed income (+3.14%) CEFs on average posted plus-side returns. At month end, 9% of all CEFs traded at a premium to their NAV, with 9% of equity CEFs and 8% of fixed income CEFs trading in premium territory. Developed Markets CEFs (+6.45%), for the second straight month, outpaced the other classifications in the equity CEF universe for December.

The Month In Closed-End Funds: December 2023

PHILADELPHIA, PA / ACCESSWIRE / October 27, 2023 / Effective close of business today, October 27, 2023, abrdn Inc. ("abrdn") assumed responsibility for the management of the four (4) former Tekla Capital Management LLC closed-end funds totaling $2.8bn in assets under management (AUM) as of October 26, 2023. As noted within the Funds' proxy statements and in connection with the change in investment adviser, each Fund amended its declaration of trust to change its name as detailed in the chart below effective after close of regular business on October 27, 2023.

abrdn Announces Its Appointment to Four U.S. Specialist Healthcare Closed-End Funds, New Board of Trustees to the Funds and Fund Name Changes

BOSTON--(BUSINESS WIRE)--Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its four closed-end funds (the Funds). The Funds are: Tekla Healthcare Investors (HQH) Tekla Life Sciences Investors (HQL) Tekla Healthcare Opportunities Fund (THQ) Tekla World Healthcare Fund (THW) Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) approved the proposal a.

Tekla Funds Approve New Investment Advisory Agreements With abrdn Inc.

Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manager to four NYSE listed healthcare and biotech thematic closed-end funds, totaling $2.8 bn in assets under management (AUM) as of October 26, 2023.

Tekla Capital Management LLC Announces Closing of Transaction With abrdn

Blackrock Health Sciences Trust

BlackRock Science and Technology Trust II

BlackRock Utilities Infrastructure & Power Opportunities Trust

ClearBridge Energy MLP Fund Inc

Central Securities

European Equity Fund

Franklin Templeton Emerging Markets Fund

Eaton Vance Tax Advantaged Global Dividend Opportunities Fund

Eaton Vance Tax-Advantaged Dividend Income Fund

Sprott Focus Trust

Gabelli Global Small and Mid Cap Value Trust

Eagle Capital Growth Fund Inc

Gabelli Healthcare & Wellness Trust

Morgan Stanley India Investment Fund Inc

Barings Corporate Investors

Barings Participation Investors

Mexico Fund

PIMCO Energy and Tactical Credit Opportunities Fund

Income Portfolio - 38 CEFs Worth Exploring

BOSTON--(BUSINESS WIRE)--On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale.

Tekla Life Sciences Investors Paid Distribution

Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth of biotech stocks thus has resulted in a huge price loss for this fund. However, the HQL closed-end fund has delivered consistent strong yields over the years. Despite poor price growth, I am bullish about the biotech sector due to aging demographics, adoption of new medical products, and robust M&A activities.

HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield

BOSTON--(BUSINESS WIRE)--Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint first special meetings of shareholders (“Special Meetings”) were adjourned for a second time until September 12, 2023 at 9:00 a.m. EDT due to lack of a quorum on the proposal to approve a new investment advisory agreement with abrdn, Inc. Shareholders as of the June 16, 2023.

Tekla Funds Announce Second Adjournment of Special Meetings and Urge Shareholder Participation to Limit the Need for Further Solicitation Efforts

BOSTON--(BUSINESS WIRE)--On August 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is August 25, 2023 and the payable date is September 29, 2023. The Fund will trade ex-distribution on August 24, 2023. Under its distribution policy, the Fund intends to make quarterly distributions at a rate of 2% of the Fund's net assets. Therefore, when the net assets of the Fund are down, the distribution per share amount will decrease a.

Tekla Life Sciences Investors Declares Distribution

BOSTON--(BUSINESS WIRE)--Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint special meetings of shareholders on August 14, 2023 (“Special Meetings”) were adjourned until August 29, 2023 to provide additional time for the Funds to reach a quorum on the proposal, described in their definitive joint proxy statement dated July 10, 2023 as filed with the.

Tekla Funds Announce Adjournment of Special Meetings

Tekla Life Sciences Investors is a closed-ended equity fund that primarily invests in the life sciences sector, with a heavy focus on biotech and pharmaceuticals.

HQL: 13% Discount Creates An Opportunity

HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution.

HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield

Virtus Artificial Intelligence & Technology Opportunities Fund

ARK Innovation ETF

BlackRock Innovation & Growth Trust

Eaton Vance Tax-Managed Buy-Write Opportunities Fund

Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund

Eaton Vance Tax-Advantaged Bond & Opportunity Stategies Fund

Voya Asia Pacific High Dividend Equity Income Fund

Voya Global Advantage and Premium Opportunity Fund

iShares Russell 1000 Growth ETF

NXG NextGen Infrastructure Income Fund

Pimco Global Stockplus & Income Fund

Invesco QQQ

SPDR S&P 500 ETF Trust

2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve that doesn't want to let up on strangling inflation into submission while draining market liquidity.

Equity CEFs: Top Picks For 2023

Virtus AllianzGI Diversified Income & Convertible Fund

BlackRock Resources & Commodities Strategy Trust

For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the broad market. For these reasons, they are not suited for everyone.

5 Best CEFs To Buy This Month (December 2022)

The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping to lower-and-lower valuations with HQH now at a -11.6% discount and HQL at a -12.0% discount.

Equity CEFs: What's Going On With Tekla's HQH And HQL?

Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point.

Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV

Tekla Life Sciences Investors is a closed-end fund focused on biotechnology and pharmaceutical stocks. The fund does not employ leverage and has an annualized 5-year total return of only 2.3% while its 10-year range annualized return sits at 9.8%.

HQL: A Biotechnology Equity CEF With No Leverage

HQL pays regular quarterly dividends with a close to double-digit yield, and despite poor price growth over medium and long run, HQL's total return is impressive. In the past three months, a dividend cut and extension of buyback period played a significant role in price movement of HQL.

HQL: Buy For The Yield, If You Can Stomach The Depreciation

BOSTON--(BUSINESS WIRE)--Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2022. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2023. The Board aut

News for abrdn Life Sciences Investors ETF (HQL)